Schizoaffective Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 74 25 54 15 17 71
Schizophreniform Psychosis, Affective Type 25
Schizophrenia, Schizo-Affective Type 25
Schizo-Affective Type Schizophrenia 25
Schizoaffective Schizophrenia 25
Schizo-Affective Psychosis 25
Schizoaffective Psychosis 25


External Ids:

Disease Ontology 12 DOID:5418
ICD9CM 34 295.7
MeSH 43 D011618
NCIt 49 C94378
SNOMED-CT 67 68890003
ICD10 32 F25 F25.9
UMLS 71 C0036337

Summaries for Schizoaffective Disorder

Genetics Home Reference : 25 Schizoaffective disorder is a mental health condition that includes features of both schizophrenia and a mood disorder such as bipolar disorder or depression. The prefix "schizo-" refers to the psychotic symptoms of schizophrenia that affect a person's thinking, sense of self, and perceptions. The term "-affective" refers to extreme shifts in mood, energy, and behavior. Schizoaffective disorder has a wide range of signs and symptoms that make it challenging to diagnose. Its features overlap significantly with those of schizophrenia and bipolar disorder, and there is debate about whether schizoaffective disorder should be considered a separate diagnosis or a subtype of one of these other conditions. Signs and symptoms of psychosis in people with schizoaffective disorder include false perceptions called hallucinations, such as hearing voices no one else can hear or experiencing visions, smells, or tactile (touch) sensations. Strongly held false beliefs (delusions) are also a characteristic feature. For example, affected individuals may be certain that they are a particular historical figure or that they are being plotted against or controlled by others. There are two major types of schizoaffective disorder, based on which mood disorder is involved: the bipolar type and the depressive type. The bipolar type includes both dramatic "highs," called manic episodes, and "lows," called depressive episodes. The depressive type includes only depressive episodes. Manic episodes are characterized by increased energy and activity, irritability, restlessness, an inability to sleep, and reckless behavior. Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks. The psychosis and mood problems associated with schizoaffective disorder usually become evident in adolescence or young adulthood. People with this condition often have difficulty functioning at school, at work, and in social settings. Disordered thinking and concentration, inappropriate emotional responses, erratic speech and behavior, and difficulty with personal hygiene and everyday tasks are also common. People with schizoaffective disorder have a higher risk of substance abuse problems and dying by suicide than the general population.

MalaCards based summary : Schizoaffective Disorder, also known as schizophreniform psychosis, affective type, is related to schizophrenia 18 and schizophrenia 9. An important gene associated with Schizoaffective Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Citalopram and Lithium carbonate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

Wikipedia : 74 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 18 33.0 SLC1A1 PRODH NRXN1
2 schizophrenia 9 33.0 PRODH DISC1
3 schizophrenia 2 32.5 PRODH DISC2 DISC1
4 schizophrenia 4 32.2 SLC1A1 PRODH
5 depression 32.0 SLC6A4 HTR2A HTR1A DISC2 BDNF
6 tardive dyskinesia 31.2 HTR2A DRD3 DRD2 COMT
7 movement disease 31.0 PRODH DRD3 DRD2
8 hyperprolactinemia 31.0 PRL HTR2A DRD2
9 galactorrhea 30.8 PRL DRD2
10 neuroleptic malignant syndrome 30.8 HTR2A HTR1A DRD3 DRD2
11 endogenous depression 30.7 SLC6A4 PRL HTR2A HTR1A COMT BDNF
12 early-onset schizophrenia 30.6 DRD2 BDNF
13 dissociative disorder 30.5 SLC6A4 HTR2A BDNF
14 amnestic disorder 30.5 HTR1A DRD2 BDNF
15 sexual disorder 30.5 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
16 traumatic brain injury 30.5 DRD2 COMT BDNF
17 brain injury 30.5 DRD2 COMT BDNF
18 mental depression 30.4 SLC6A4 PRODH HTR2A HTR1A DRD3 DRD2
19 constipation 30.4 SLC6A4 NRXN1 HTR2A HTR1A BDNF
20 digeorge syndrome 30.4 PRODH NRXN1 DISC1 COMT
21 opiate dependence 30.4 SLC6A4 DRD3 DRD2
22 personality disorder 30.4 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
23 conversion disorder 30.3 HTR2A COMT
24 obsessive-compulsive personality disorder 30.3 SLC6A4 HTR2A DRD3 COMT
25 conduct disorder 30.3 SLC6A4 DRD2 COMT
26 speech and communication disorders 30.3 PRODH DRD2 COMT BDNF
27 tobacco addiction 30.2 SLC6A4 NRXN1 HTR2A DRD3 DRD2 COMT
28 substance abuse 30.2 SLC6A4 PRODH PRL HTR2A HTR1A DRD3
29 fragile x syndrome 30.2 SLC6A4 PRODH NRXN1 BDNF
30 dystonia 30.2 PRL HTR2A DRD3 DRD2 COMT BDNF
31 cocaine abuse 30.1 SLC6A4 PRL DRD3 DRD2 BDNF
32 delusional disorder 30.1 PRL HTR2A HTR1A DRD3 DRD2
33 borderline personality disorder 30.1 SLC6A4 PRL HTR2A HTR1A DRD2 COMT
34 paranoid schizophrenia 30.1 SLC6A4 PRL NRXN1 HTR2A HTR1A DISC1
35 obsessive-compulsive disorder 30.1 SLC6A4 SLC1A1 PRL HTR2A HTR1A DRD3
36 neurotic disorder 30.1 SLC6A4 HTR2A HTR1A BDNF
37 schizophrenia 1 30.1 DTNBP1 DISC1 DAOA
38 alcohol dependence 30.0 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
39 cocaine dependence 30.0 SLC6A4 PRL HTR2A DRD3 DRD2 COMT
40 post-traumatic stress disorder 30.0 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
41 dementia 29.9 HTR2A HTR1A DRD2 COMT BDNF
42 alcohol use disorder 29.9 SLC6A4 HTR2A HTR1A DRD3 DRD2 COMT
43 pathological gambling 29.9 SLC6A4 HTR2A HTR1A DRD3 DRD2 COMT
44 mood disorder 29.9 SLC6A4 PRODH HTR2A HTR1A DRD3 DRD2
45 anxiety 29.8 SLC6A4 SLC1A1 PRODH PRL HTR2A HTR1A
46 anorexia nervosa 29.8 SLC6A4 PRL HTR2A HTR1A COMT BDNF
47 bipolar i disorder 29.8 SLC6A4 HTR2A HTR1A DTNBP1 DRD3 DRD2
48 social phobia 29.7 SLC6A4 PRODH PRL HTR1A DRD2 COMT
49 schizophreniform disorder 29.7 PRODH PRL HTR2A DTNBP1 DRD3 DRD2
50 panic disorder 29.6 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2

Graphical network of the top 20 diseases related to Schizoaffective Disorder:

Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DRD2 HTR2A NRG3 NRXN1
3 homeostasis/metabolism MP:0005376 9.8 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
4 nervous system MP:0003631 9.53 BDNF COMT DISC1 DRD2 DRD3 DTNBP1

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Citalopram Approved Phase 4 59729-33-8 2771
Lithium carbonate Approved Phase 4 554-13-2
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Ziprasidone Approved Phase 4 146939-27-7 60854
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
Perphenazine Approved Phase 4 58-39-9 4748
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Pravastatin Approved Phase 4 81093-37-0 54687
Molindone Approved Phase 4 7416-34-4 23897
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Norepinephrine Approved Phase 4 51-41-2 439260
Pimozide Approved Phase 4 2062-78-4 16362
Fluphenazine Approved Phase 4 69-23-8 3372
22 Perazine Approved, Investigational Phase 4 84-97-9
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
Benperidol Approved, Investigational Phase 4 2062-84-2
25 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
30 Coconut Approved Phase 4
Histamine Approved, Investigational Phase 4 51-45-6 774
Lorazepam Approved Phase 4 846-49-1 3958
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
Acetaminophen Approved Phase 4 103-90-2 1983
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
Ondansetron Approved Phase 4 99614-02-5 4595
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Losartan Approved Phase 4 114798-26-4 3961
Ethanol Approved Phase 4 64-17-5 702
Clozapine Approved Phase 4 5786-21-0 2818
Amantadine Approved Phase 4 768-94-5 2130
Galantamine Approved Phase 4 357-70-0 9651
Iloperidone Approved Phase 4 133454-47-4 71360
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 526)
# Name Status NCT ID Phase Drugs
1 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
2 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
3 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
4 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
5 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
6 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
7 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
8 A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Completed NCT00649064 Phase 4 Ziprasidone
9 Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
10 The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
11 A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder Completed NCT00406315 Phase 4 ziprasidone
12 Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder. Completed NCT00304655 Phase 4 Aripiprazole
13 A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
14 A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder Completed NCT02137993 Phase 4 A-prexa;Zyprexa
15 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
16 Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone Completed NCT00190749 Phase 4 olanzapine;risperidone
17 A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression Completed NCT00034801 Phase 4 olanzapine;ziprasidone
18 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
19 The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial Completed NCT00224822 Phase 4 Aripiprazole
20 Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
21 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
22 Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study Completed NCT00650429 Phase 4 Ziprasidone
23 A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
24 Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial Completed NCT00224315 Phase 4 ziprasidone;risperidone
25 A Comparison of Long-Acting Injectable Medications for Schizophrenia Completed NCT01136772 Phase 4 haloperidol decanoate;paliperidone palmitate
26 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
27 A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder Completed NCT00061802 Phase 4 risperidone, quetiapine
28 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
29 Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT01198353 Phase 4 Ziprasidone
30 A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00222794 Phase 4 Atomoxetine (Strattera)
31 An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00501618 Phase 4 Fazaclo
32 A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
33 A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Completed NCT00845507 Phase 4 Exenatide;Placebo
34 BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
35 Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Completed NCT00216632 Phase 4 risperidone
36 The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
37 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study Completed NCT00802919 Phase 4 Varenicline;Placebo for varenicline
38 A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00177580 Phase 4 Pravastatin
39 Treatment of Schizophrenia and Related Disorders in Children and Adolescents Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
40 A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders Completed NCT00253110 Phase 4 risperidone;haloperidol
41 Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study Completed NCT00816907 Phase 4 Metformin;Placebo
42 Clinical Management of Metabolic Problems in Patients With Schizophrenia Completed NCT00423878 Phase 4 Risperidone;Olanzapine;Quetiapine;Aripiprazole
43 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
44 A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
45 High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia Completed NCT01569659 Phase 4 Lurasidone;Lurasidone
46 An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
47 A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00236379 Phase 4 Olanzapine;Risperidone
48 The Effect of Switching to Aripiprazole on Indices of Cardiovascular Health in Overweight and Obese Patients With Schizophrenia Completed NCT00222833 Phase 4 Aripiprazole
49 A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine Completed NCT00378183 Phase 4 risperidone
50 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo

Search NIH Clinical Center for Schizoaffective Disorder

Genetic Tests for Schizoaffective Disorder

Anatomical Context for Schizoaffective Disorder

MalaCards organs/tissues related to Schizoaffective Disorder:

Brain, Testes, Cortex, Heart, Eye, Prefrontal Cortex, Liver

Publications for Schizoaffective Disorder

Articles related to Schizoaffective Disorder:

(show top 50) (show all 4224)
# Title Authors PMID Year
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. 61 54
20521326 2010
Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. 61 54
19551763 2009
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. 54 61
19336781 2009
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 54 61
19200422 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. 61 54
19142110 2009
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. 61 54
18786813 2008
Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. 61 54
18628679 2008
Does diagnostic classification of early-onset psychosis change over follow-up? 61 54
17665305 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. 61 54
18320559 2008
Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia. 61 54
17504246 2008
Dysbindin gene variants are associated with bipolar I disorder in a Korean population. 54 61
17433541 2007
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 61 54
17267179 2007
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. 54 61
16478753 2006
COMT genotype and manic symptoms in schizophrenia. 61 54
16828262 2006
BDNF gene variants and brain morphology in schizophrenia. 61 54
16741916 2006
Hyperprolinemia is not associated with childhood onset schizophrenia. 54 61
16389584 2006
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. 61 54
16380905 2005
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 54 61
16232322 2005
Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. 54 61
16203953 2005
DISC1 and neurocognitive function in schizophrenia. 54 61
16056147 2005
A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. 61 54
15940305 2005
Hyperprolinemia is a risk factor for schizoaffective disorder. 61 54
15494707 2005
Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population. 61 54
15567076 2005
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. 61 54
15386212 2004
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 61 54
15362017 2004
ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence. 54 61
15274028 2004
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. 61 54
15121646 2004
Long-term observational comparison of risperidone and olanzapine in bipolar disorder. 61 54
15328900 2004
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 61 54
14744169 2004
Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. 61 54
15184103 2004
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. 61 54
12140115 2002
NOTCH4 gene polymorphism and susceptibility to schizophrenia and schizoaffective disorder. 54 61
11239712 2001
[Levels and molecular heterogeneity of serotonin transporter protein in platelets of patients with different mental diseases: a comparative analysis with the use of monoclonal and polyclonal antibodies]. 54 61
11523428 2001
Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. 61 54
11060712 2000
Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees. 61 54
9988837 1999
A genome-wide search for schizophrenia susceptibility genes. 61 54
9754621 1998
Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naive psychotic patients before and after treatment with haloperidol. 54 61
19698552 1997
A comparison of cognitive profiles in schizophrenia and other psychiatric disorders. 54 61
8771446 1996
Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. 54 61
7944879 1994
Self-other differentiation among psychotic and conduct-disordered adolescents as measured by human figure drawings. 54 61
8483645 1993
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 54 61
8439241 1993
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. 54 61
2255750 1990
Subjective Recovery in Patients with Schizophrenia and Related Factors. 61
32277339 2020
How Early Life Adversities Influence Later Life Family Interactions for Individuals with Schizophrenia in Outpatient Treatment: A Qualitative Analysis. 61
32385585 2020
Genome-wide association study of aggression and violence in schizophrenia. 61
32445792 2020
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. 61
32015461 2020
How reasonable is it to uphold the diagnostic concept of schizoaffective disorder? 61
32353169 2020
An Observational Retrospective Study Investigating Changes in Seizure Adequacy Parameters of Electroconvulsive Therapy and Their Relationships to Clinical Outcome in Schizophrenia and Schizoaffective Disorder. 61
32525703 2020
Valproate and Neuroleptic Malignant Syndrome in an Elderly Patient With Schizoaffective Disorder. 61
32530580 2020
A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations. 61
32517724 2020

Variations for Schizoaffective Disorder

Expression for Schizoaffective Disorder

Search GEO for disease gene expression data for Schizoaffective Disorder.

Pathways for Schizoaffective Disorder

GO Terms for Schizoaffective Disorder

Cellular components related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.29 SLC6A4 SLC1A1 RGS4 PCDH11X NRXN1 NRG3
2 cell junction GO:0030054 10.01 SLC6A4 SLC1A1 NRXN1 HTR2A DTNBP1 DISC1
3 dendrite GO:0030425 9.85 SLC1A1 HTR2A HTR1A DRD2 COMT BDNF
4 integral component of plasma membrane GO:0005887 9.85 SLC6A4 SLC1A1 PCDH11X NRXN1 NRG3 NOTCH4
5 glutamatergic synapse GO:0098978 9.8 NRXN1 NRG3 HTR2A DTNBP1 DRD3 DRD2
6 dendritic spine GO:0043197 9.73 SLC1A1 DTNBP1 DRD2 COMT
7 presynapse GO:0098793 9.71 SLC6A4 SLC1A1 NRXN1 HTR2A
8 synaptic vesicle membrane GO:0030672 9.7 DTNBP1 DRD3 DRD2
9 GABA-ergic synapse GO:0098982 9.69 NRXN1 DRD3 DRD2
10 endocytic vesicle GO:0030139 9.67 NRXN1 DRD3 DRD2
11 integral component of postsynaptic membrane GO:0099055 9.63 SLC6A4 HTR2A DRD2
12 asymmetric synapse GO:0032279 9.56 SLC1A1 DTNBP1
13 integral component of presynaptic membrane GO:0099056 9.56 SLC6A4 NRXN1 HTR2A DRD2
14 dopaminergic synapse GO:0098691 9.55 DRD3 DRD2
15 axon GO:0030424 9.5 SLC1A1 HTR2A DTNBP1 DRD2 DISC1 COMT
16 synapse GO:0045202 9.28 SLC6A4 SLC1A1 NRXN1 HTR2A HTR1A DTNBP1

Biological processes related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.92 SLC1A1 NRXN1 HTR2A HTR1A
2 response to ethanol GO:0045471 9.84 RGS4 DRD3 DRD2
3 response to toxic substance GO:0009636 9.82 SLC6A4 DRD3 DRD2
4 modulation of chemical synaptic transmission GO:0050804 9.8 NRG3 DRD2 BDNF
5 memory GO:0007613 9.8 SLC6A4 HTR2A BDNF
6 learning GO:0007612 9.77 NRXN1 DRD3 COMT
7 synapse assembly GO:0007416 9.76 NRXN1 DRD2 BDNF
8 regulation of synaptic vesicle exocytosis GO:2000300 9.75 HTR2A DTNBP1 DRD2
9 social behavior GO:0035176 9.74 SLC6A4 NRXN1 DRD3
10 response to cocaine GO:0042220 9.71 RGS4 DRD3 DRD2
11 response to amphetamine GO:0001975 9.7 RGS4 DRD3 DRD2
12 synaptic transmission, dopaminergic GO:0001963 9.67 DRD3 DRD2
13 negative regulation of cytosolic calcium ion concentration GO:0051481 9.67 DRD3 DRD2
14 vasoconstriction GO:0042310 9.66 SLC6A4 HTR1A
15 negative regulation of voltage-gated calcium channel activity GO:1901386 9.66 DRD3 DRD2
16 behavioral response to ethanol GO:0048149 9.65 DRD3 DRD2
17 behavior GO:0007610 9.65 HTR2A HTR1A
18 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.64 DRD3 DRD2
19 positive regulation of renal sodium excretion GO:0035815 9.64 DRD3 DRD2
20 G protein-coupled receptor internalization GO:0002031 9.63 DRD3 DRD2
21 mammary gland development GO:0030879 9.63 PRL NRG3 NOTCH4
22 response to drug GO:0042493 9.63 SLC6A4 HTR2A DRD3 DRD2 COMT BDNF
23 regulation of potassium ion transport GO:0043266 9.61 DRD3 DRD2
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD3 DRD2
25 response to morphine GO:0043278 9.61 RGS4 DRD3 DRD2
26 serotonin receptor signaling pathway GO:0007210 9.6 HTR2A HTR1A
27 behavioral response to cocaine GO:0048148 9.58 HTR2A DRD3 DRD2
28 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.56 DRD3 DRD2
29 regulation of neurotransmitter uptake GO:0051580 9.55 DRD3 DRD2
30 prepulse inhibition GO:0060134 9.54 NRXN1 DRD3 DRD2
31 regulation of locomotion involved in locomotory behavior GO:0090325 9.51 DRD3 DRD2
32 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.5 HTR2A DRD3 DRD2
33 acid secretion GO:0046717 9.49 DRD3 DRD2
34 response to histamine GO:0034776 9.48 DRD3 DRD2
35 dopamine metabolic process GO:0042417 9.43 DRD3 DRD2 COMT
36 regulation of dopamine secretion GO:0014059 9.26 HTR2A DTNBP1 DRD3 DRD2
37 negative regulation of dopamine receptor signaling pathway GO:0060160 8.8 RGS4 DRD3 DRD2

Molecular functions related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 HTR2A DRD3 DRD2
2 adrenergic receptor activity GO:0004935 9.37 DRD3 DRD2
3 dopamine binding GO:0035240 9.32 DRD3 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD3 DRD2
5 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
6 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Schizoaffective Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....